Loading...
Loading...
$493.5K
Awarded Mar 30, 2026
Competition
FULL AND OPEN COMPETITION
Offers
N/A
Set-Aside
None
Solicitation Type
RFP - Negotiated
Performance Timeline
Start
Mar 13, 2026
This contract is likely in the recompete window.
Watch for new solicitations from Department of Health and Human Services.
Contract: 75A50126F61020
UEI
FRHTPHMZMX47
Parent Company
GLAXOSMITHKLINE, LLC
Capabilities & Certifications
Headquarters Location
Congressional District: 04
Current Obligation
$493,470
Base + Exercised Options
$493,470
Total Ceiling Value
$493,470
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
Description
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
DRUGS AND BIOLOGICALS
Place of Performance
Congressional District: 04
Awarding Agency
Top-tier Agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier Agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Funding Agency
Top-tier Agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier Agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Contract Vehicle
75A50122D00002
IDCDepartment of Health and Human Services
Award Type: SINGLE AWARD